Company intelligence / Profile preview
Medibiofarma
Pamplona* / Cordovilla*, Navarra, Spainmedibiofarma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Medibiofarma develops disease-modifying therapies for serious conditions with high unmet medical need, focusing on small molecule drugs targeting well‐validated biological pathways. The company aims to de-risk assets by advancing them through proof-of-concept clinical trials before licensing. Its pipeline includes programs for cancer and neurodegenerative disorders, though specific trial results are not publicly detailed.
- Therapeutic areas
- OtherOncologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
CROs/universities/research centers
Beyond the preview
Go deeper on Medibiofarma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Medibiofarma.